Clinical Advances in Nasopharyngeal Carcinoma - Episode 3

Overview of the JUPITER and POLARIS-2 Trials

, ,

Victoria M. Villaflor, MD, provides insights on the role of immune checkpoint inhibitors in treating nasopharyngeal carcinoma, focusing on the JUPITER and POLARIS-2 clinical trials.

EP. 1: Differentiating Nasopharyngeal Carcinoma from Other Head & Neck Cancers: The Value of a Multidisciplinary Approach
EP. 2: Current Guidelines for Managing Nasopharyngeal Carcinoma
Now Viewing
EP. 3: Overview of the JUPITER and POLARIS-2 Trials
EP. 4: Value of PD-L1 Biomarker in NPC
EP. 5: Phase 3 DIPPER Trial: Adjuvant PD-1 Blockade with Camrelizumab
EP. 6: Tailoring NPC Treatment: Patient Populations, EBV Titer Monitoring, and Key External Factors
EP. 7: Strategies to Mitigate Adverse Events in Nasopharyngeal Carcinoma Treatment
EP. 8: Future Research Needs for Neoadjuvant/Adjuvant PD-1 Blockade in Nasopharyngeal Carcinoma
EP. 9: Integrating PD-1 Inhibitors into Standard NPC Treatment: Potential Benefits and Future Prospects
EP. 10: Clinical Scenario: Locally Recurrent NPC

Video content above is prompted by the following:

  • Have you had clinical experience with immune checkpoint inhibitors in combination with chemotherapy for your patients with NPC?
  • Please give your thoughts on the JUPITER and POLARIS-2 trials in NPC.

Related Content:

Clinical Advances in Nasopharyngeal CarcinomaYale Cancer CenterCity of HopeHead & Neck CancersInsights
Dr Amanam on the Optimal Use of JAK Inhibitors in the Current Myelofibrosis Treatment Paradigm
Clinical Scenario: Locally Recurrent NPC
Integrating PD-1 Inhibitors into Standard NPC Treatment: Potential Benefits and Future Prospects